about
Phenotyping dividing cells in mouse models of neurodegenerative basal ganglia diseases.Identification of age-dependent motor and neuropsychological behavioural abnormalities in a mouse model of Mucopolysaccharidosis Type IIPhenotypic effects of maternal immune activation and early postnatal milieu in mice mutant for the schizophrenia risk gene neuregulin-1.Resolving pathobiological mechanisms relating to Huntington disease: gait, balance, and involuntary movements in mice with targeted ablation of striatal D1 dopamine receptor cells.Motor and behavioral phenotype in conditional mutants with targeted ablation of cortical D1 dopamine receptor-expressing cells.Macrophage enzyme and reduced inflammation drive brain correction of mucopolysaccharidosis IIIB by stem cell gene therapy.Epistatic and Independent Effects on Schizophrenia-Related Phenotypes Following Co-disruption of the Risk Factors Neuregulin-1 × DISC1.A non-myeloablative chimeric mouse model accurately defines microglia and macrophage contribution in glioma.A novel adeno-associated virus capsid with enhanced neurotropism corrects a lysosomal transmembrane enzyme deficiency.Brain-targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms.Non-myeloablative busulfan chimeric mouse models are less pro-inflammatory than head-shielded irradiation for studying immune cell interactions in brain tumoursStrategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type IHaematopoietic stem cell gene therapy with IL-1Ra rescues cognitive loss in mucopolysaccharidosis IIIAAn Improved Adeno-Associated Virus Vector for Neurological Correction of the Mouse Model of Mucopolysaccharidosis IIIAAcute stress in adolescence vs early adulthood following selective deletion of dysbindin-1A: Effects on anxiety, cognition and other schizophrenia-related phenotypes
P50
Q35007247-6549F194-E1CD-4187-89AB-92B27745DD3BQ36282902-03430EB6-3235-45D9-B851-648BA43219ECQ42208739-819CA14F-C5AA-42F6-954A-390AEE0973B9Q44777384-EF2F666C-BC51-4F55-AAB0-7C2B6185540CQ45304269-CE7DFA8D-94C1-482D-82E9-B9B76350644AQ45875162-C600DC5F-BB9B-4603-B8E5-267C578D5DBAQ48520616-0C644445-44AE-4832-8F2C-C72886BE831FQ52573142-4441CC53-A7E1-4A89-A4BA-6C8CD85F5012Q55620891-76E1524E-94D3-4DE0-9C8D-4768768C68C0Q55658045-F4AB6918-A0C0-401F-96BF-5AF5454E1761Q61799353-83E6DB57-4FB1-48FB-BA15-AB217607E2B3Q64072336-289645FB-8413-4FF8-AA09-CF6A732071C3Q89710968-140F9B7D-3A3B-42FA-AF3F-2A6AF26ABAD8Q90295911-42FAB92F-0CAC-4ADB-92CE-48B884AD5C58Q90303196-83EA64BB-CBDC-4A87-A9F8-95E4C4351643
P50
description
researcher
@en
wetenschapper
@nl
name
C O'Leary
@en
C O'Leary
@nl
type
label
C O'Leary
@en
C O'Leary
@nl
prefLabel
C O'Leary
@en
C O'Leary
@nl
P31
P496
0000-0001-8616-7466